SCHEDULE 13G: T. Rowe Price Associates Discloses 5.4% Stake in Celldex Therapeutics

T. Rowe Price Associates, Inc. has disclosed a 5.4% beneficial ownership stake in Celldex Therapeutics Inc., holding 3,557,136 shares of common stock as of December 31, 2024.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting its beneficial ownership in CELLDEX THERAPEUTICS INC.
• As of December 31, 2024, T. Rowe Price Associates, Inc. beneficially owned 3,557,136 shares of Celldex Therapeutics Inc.'s common stock.
• This ownership represents 5.4% of the total outstanding common stock of Celldex Therapeutics Inc.
• T. Rowe Price Associates, Inc. holds sole voting power over 3,477,646 shares and sole dispositive power over all 3,557,136 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a major institutional investor like T. Rowe Price Associates is generally viewed positively by the market, indicating confidence in the company, although the filing itself is a routine compliance matter and does not imply active engagement or control.

Positives

• The disclosure of a significant 5.4% stake by a major institutional investor like T. Rowe Price Associates, Inc. can be interpreted as a vote of confidence in Celldex Therapeutics Inc.'s long-term prospects and business strategy.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment approach by T. Rowe Price Associates, Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Celldex Therapeutics Inc.'s future financial performance or strategic direction, as it is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• T. Rowe Price Associates, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
• T. Rowe Price Associates, Inc. declared and affirmed that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

This filing represents a routine disclosure by a large, established asset management firm, T. Rowe Price Associates, Inc., indicating a passive investment in Celldex Therapeutics Inc., a company operating within the biotechnology and pharmaceutical sectors. Such institutional investments are common and reflect portfolio allocation decisions.

Stakeholder Impact

• Shareholders of Celldex Therapeutics Inc. may perceive the investment by T. Rowe Price Associates, Inc. as a positive signal, potentially bolstering investor confidence and market perception of the company's value.
• The company's management may view this as validation of their strategy, though it does not imply any direct influence or control from T. Rowe Price Associates, Inc.

Next Steps

• T. Rowe Price Associates, Inc. will be required to file amendments to this Schedule 13G if there are material changes to its beneficial ownership of Celldex Therapeutics Inc.'s common stock, such as crossing certain percentage thresholds or changing its investment intent.

Key Dates

Keywords

Celldex Therapeutics, T. Rowe Price Associates, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals